Place of GLP-1RAs in the Treatment of Obesity Currently, pharmacotherapy is recommended as an adjunct to lifestyle modification for individuals with a BMI of at least 30 kg/m 2 , or at least 27 kg/m 2 with comorbidity [5, 9]
D., Bluher, M., Tschop, M
While its not common, some patients on thyroid hormone replacement medication will require dose adjustments after starting GLP-1s
In fact, a 2024 analysis revealed that only 13 state Medicaid programs covered GLP-1s for obesity treatment, and many of these plans imposed stringent criteria such as prior authorization and BMI thresholds
Meanwhile, 78% of GLP-1 users who bought its products to maintain or improve results found it to be effective at curbing cravings and supporting weight management
Early weight loss may occur during the first month, while more substantial changes often become apparent over several months